Influence of intensive statin therapy on level of serum interleukin-37 in patients with acute coronary syndrome

CHEN Shao-yuan; FANG Hong-cheng; JIN Jian; XIE Pei-yi; FANG Ye-qing; SU You-su

doi:10.3969/j.1674-4055.2014.04.08

Abstract：Objective To observe the changes of serum interleukin-37 (IL-37) level in patients with acute coronary syndrome (ACS) treated with atorvastatin in different doses, and discuss the influences of intensive statin therapy on IL-37 level and coronary atherosclerotic plaques. Methods ACS patients (n=110) with planed PCI were randomly divided into 3 groups, including routine therapy group treated with atorvastatin (20 mg/night), intensive group A treated with atorvastatin (40 mg/night and 20 mg/night after 4 w) and intensive group B treated with atorvastatin (80 mg once, then 40 mg/night and 20 mg/night after 4 w). The level of serum IL-37 was detected by using ELISA before and after treatment. Results ①The level of serum IL-37 showed a gradual increasing tendency during 4-w treatment (P<0.05). ②The difference in level of serum IL-37 had statistical significant in routine therapy group compared with other 2 groups after treatment for 4 w (P<0.05). ③The difference in left ventricular function and calibration TIMI frame count (CTFC) had statistical significant in routine therapy group compared with other 2 groups (P<0.05). ④The level of serum IL-37 and clinical outcomes had no statistical difference between intensive group A and intensive group B after treatment for 4 w. ⑤The incidence of major adverse cardiovascular events (MACE) and adverse drug reactions had no statistical difference among 3 groups after 4 w. Conclusion The level of serum IL-37 can be taken as an index for monitoring and reviewing ACS patients. Intensive statin therapy can promote the level of serum IL-37 (anti-inflammatory cytokine), and improve CTFC and left ventricular function without the increase of adverse drug reactions.